Growth HormoneEmerging

CJC-1295

A GHRH analog with a DAC modification that extends half-life, enabling once or twice-weekly dosing for sustained GH elevation.

Also known as: GRF (1-29), GHRH Analog

Subcutaneous

Available on Forge Amino

CJC-1295 / Ipamorelin Blend — independently lab tested, 99%+ purity, QR-linked COA.

Source this compound →

Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.

How It Works

Binds GHRH receptors on somatotroph cells, stimulating GH synthesis and pulsatile release. DAC (Drug Affinity Complex) enables albumin binding for 6-10 day half-life.

Key Benefits

  • 2-10 fold GH elevation sustained 6+ days
  • 1.5-3 fold IGF-I elevation
  • Enhanced muscle protein synthesis
  • Visceral fat reduction
  • Improved sleep quality

Dosing Protocols

Beginner / Intermediate

Dose

100 mcg

Frequency

Before bed subcutaneous

Cycle Length

8-12 weeks

Notes

Inject on empty stomach; fast 90-120 min before and 30-60 min after

Advanced

Dose

100-200 mcg

Frequency

Twice daily subcutaneous

Cycle Length

12-16 weeks

Notes

Stack with ipamorelin for synergistic GH pulse amplification

Side Effects & Safety

Common Side Effects

  • Flushing or warmth sensation
  • Water retention and mild edema
  • Headache or dizziness
  • Joint pain (from IGF-I elevation)

Contraindications

  • Pregnancy and breastfeeding
  • Active cancer or cancer history
  • Acute critical illness
  • Pre-diabetes (caution: insulin antagonism)
  • Acromegaly or pituitary disease

Stacking & Synergies

These compounds have complementary mechanisms and may enhance results when used together.

IpamorelinSermorelinResistance trainingAdequate sleep

Key Takeaway

Sustained GH elevation: CJC-1295 extends GHRH signaling for days with convenient weekly dosing.

Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.